TMCnet News
Interleukin Genetics and Employee Benefit Consulting Group LLC Partner to Expand Awareness and Adoption of PerioPredict®Interleukin Genetics, Inc. (OTCQB:ILIU) and Employee Benefit Consulting Group LLC (EBCG) announced today the signing of a collaboration agreement to help expand knowledge and potential coverage for Interleukin's novel genetic risk test, PerioPredict®. PerioPredict® is an innovative, easy-to-use tool that identifies individuals with a higher risk of progressing to severe periodontal disease. This collaboration was formed to leverage the rapidly growing field of genetic testing as part of an approach to more effective overall healthcare management. Predictive genetic tests identify genetic variations that may affect a patient's risk of developing a certain disease, thus enabling the patient and the healthcare professional to engage in more aggressive preventative care, and assist with treatment decisions. PerioPredict® works by measuring variations in the genes for Interleukin-1 (IL-1), a key mediator of inflammation, and identifies individuals at increased risk for more severe periodontal disease, also known as periodontitis or gum disease. Under the terms of this strategic collaboration, Interleukin and EBCG will work together to build awareness of PerioPredict® as a powerful tool for personalizing patient care among insurance carriers, benefit plans and employer groups, and to potentially incorporate the test in the design of risk-based benefit plans. "EBCG has expertise in the U.S. insurance market with strong relationships with employers, insurance carriers, and health and wellness providers, and they are an ideal collaborator as we work to expand the ongoing commercial rollout of PerioPredict®," said Dr. Kenneth S. Kornman, DDS, PhD, Chief Executive Officer of Interleukin. "We believe that PerioPredict® offers the potential to improve outcomes for patients and ultimately reduce long-term healthcare expenses associated with both oral health and other chronic inflammatory conditions related to oral health, such as cardiovascular disease and diabetes. We are excited to be working with EBCG and are confident they will be a valuable partner in enabling PerioPredict® to achieve its full clinical and market potential." Personalized medicine, including genetic tests, is becoming an integral and rapidly growing component of overall healthcare," said Dr. Alan Vogel, DMD, MPH, Senior Consultant at EBCG. "Interleukin's PerioPredict® test places them at the forefront of innovation for periodontitis risk identification, an extremely common condition which is estimated to affect approximately 47% of the U.S. adult population. Educating and raising awareness among payers and employers regarding the benefits of including genetic testing in their policies is a key tool to realizing this product's full potential. We see the PerioPredict® test as being consistent with the trend toward healthcare solutions that guide better prevention of disease, thereby improving health outcomes and reducing cost." About Periodontitis Periodontitis is a chronic inflammatory disease initiated by specific bacteria that activate hst mechanisms destroying the bone and connective tissues that support the teeth. Between 8% and 13% of the worldwide adult population exhibit severe generalized periodontitis, with many more having clinical signs of mild to moderate disease. Individuals who have a history of periodontitis and have been appropriately treated require more preventive care to maintain health. Although bacteria cause the disease, a small number of risk factors, including smoking, diabetes, IL-1 gene variations, obesity, stress, osteoporosis, and other inflammatory diseases have been associated with increased severity of periodontitis. Current treatments to prevent gum disease include good oral hygiene and professional dental cleanings on a regular basis depending on the needs of the patient. Data from the "Patient Stratification for Preventive Dental Care" study (Giannobile et al., June 2013) indicate that individuals with certain risk factors, including IL-1 gene variations, benefit significantly from cleanings twice annually, and patients with multiple risk factors appeared to require more than two cleanings annually to maintain health. The Company believes risk stratification of patients without a history of periodontitis may optimize preventative dental care to improve outcomes. About PerioPredict® The PerioPredict® genetic test is quick, easy and painless and is performed by dentists during a routine exam or cleaning. PerioPredict® measures variations in genes for Interleukin-1 (IL-1), a key mediator of inflammation, and identifies individuals who are at increased risk for moderate to severe periodontal disease. The PerioPredict® test results provide important information to the dental professional for assessing prevention and treatment options for their patients. PerioPredict® is run solely in the Interleukin Genetics CLIA-certified lab in Waltham, MA. For more information, please visit www.PerioPredict.com. About Employee Benefit Consulting Group LLC Employee Benefit Consulting Group LLC is a unique consulting firm focused on its clients' benefit programs. Attraction and retention of high performing employees takes more than a paycheck. The right benefits package allows a company to find, reward, and keep the best employees. Employee Benefit Consulting Group LLC introduces a holistic approach to benefits program consulting. EBCG understands core benefit plan strategies and supports them with innovative concepts and tailored solutions. The firm's guiding principle is to align the benefit program strategies with the business objectives of its clients thereby helping to retain key talent, increase productivity and control overall costs. More information is at www.ebenefitconsulting.com. About Interleukin Genetics Interleukin Genetics, Inc. (OTCQB: ILIU) develops and markets proprietary genetic tests for chronic diseases and health related conditions. The products empower individuals to prevent certain chronic conditions and manage their existing health and wellness through genetic-based insights with actionable guidance. Interleukin Genetics leverages its research, intellectual property and genetic panel development expertise in metabolism and inflammation to facilitate the emerging personalized healthcare market. The Company markets its tests through partnerships with health and wellness companies, healthcare professionals and other distribution channels. Interleukin Genetics' lead products include its proprietary PerioPredict® genetic risk panel for periodontal disease and tooth loss susceptibility available through dentists, and the Inherent Health® Weight Management Genetic Test that identifies the most effective diet program for an individual based on genetics. Interleukin Genetics is headquartered in Waltham, MA, and operates an on-site, state-of-the-art DNA testing laboratory certified under the Clinical Laboratories Improvements Amendments (CLIA). For more information, please visit www.ilgenetics.com. Forward-Looking Statements Certain statements contained herein are "forward-looking" statements, including statements that Interleukin and EBCG will work together to build awareness of PerioPredict® and to potentially incorporate the test in the design of risk-based benefit plans, that PerioPredict® offers the potential to improve outcomes for patients and ultimately reduce long-term healthcare expenses associated with both oral health and other chronic inflammatory conditions related to oral health, and that EBCG will be a valuable partner in enabling PerioPredict® to achieve its full clinical and market potential. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, those risks and uncertainties described in the Company's annual report on Form 10-K for the year ended December 31, 2014, and other filings with the Securities and Exchange Commission. The Company disclaims any obligation or intention to update these forward-looking statements.
|
